Skuticizumab Injection is a human interleukin-17α antagonist that is effective in the treatment of adult patients with moderate to severe plaque psoriasis or ankylosing spondylitis who meet the indications for systemic therapy or phototherapy. Skuclizumab Injection reduces epidermal neutrophil and IL-17α levels in psoriatic plaques. This is a humanized monoclonal antibody that selectively binds to the cytokine known as interleukin-17α (IL-17α) and inhibits its interaction with the IL-17 receptor. This drug is effective in the treatment of psoriasis, but you need to use this product under the guidance and supervision of an experienced physician. This product is given because of subcutaneous injection and is followed up appropriately at regular intervals. Some patients may experience adverse reactions such as infection, neutropenia, and hypersensitivity reactions. It is contraindicated in patients with severe hypersensitivity reactions to the active ingredient or any of the excipients of the product, important active infections. It is recommended to visit the hospital in time for the emergence of related diseases, and follow the doctor’s instructions to use medication for treatment.